Strid Group LLC lessened its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) by 37.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,166 shares of the company’s stock after selling 11,053 shares during the period. Strid Group LLC’s holdings in Palvella Therapeutics were worth $409,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Spire Wealth Management bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $70,000. Citadel Advisors LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter worth approximately $125,000. Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $533,000. AWM Investment Company Inc. bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $1,943,000. Finally, Royce & Associates LP bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $2,002,000. Institutional investors own 40.11% of the company’s stock.
Palvella Therapeutics Price Performance
PVLA opened at $65.78 on Friday. The firm has a market cap of $727.53 million, a P/E ratio of -5.44 and a beta of -0.13. Palvella Therapeutics, Inc. has a 1-year low of $11.17 and a 1-year high of $65.80. The company has a 50 day simple moving average of $51.46 and a two-hundred day simple moving average of $34.12.
Wall Street Analyst Weigh In
PVLA has been the topic of several analyst reports. Lifesci Capital began coverage on shares of Palvella Therapeutics in a research note on Monday, August 4th. They issued an “outperform” rating and a $90.00 target price on the stock. Stifel Nicolaus boosted their price objective on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Chardan Capital boosted their price objective on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 26th. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Finally, Truist Financial boosted their price objective on shares of Palvella Therapeutics from $56.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $69.27.
Check Out Our Latest Stock Analysis on PVLA
Palvella Therapeutics Company Profile
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
See Also
- Five stocks we like better than Palvella Therapeutics
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- How to Read Stock Charts for Beginners
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report).
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.